Biotechnology
IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma
SHANGHAI and NANJING, China and SAN JOSE, Calif., March 29, 2024 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced thatChina National Medical Products Administratio...
Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights
SUZHOU, China, March 29, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2023 and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "In 2023, Alphamab Onc...
Jacobio Pharma Announces 2023 Annual Results
BEIJING, SHANGHAI and BOSTON, March 28, 2024 Jacobio/PRNewswire/ -- Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue wasRMB63.5 million, the R&D investment wasRMB372 million, the cash and cash equivalent at...
Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade
SEONGNAM, South Korea and ATLANTA, March 28, 2024 /PRNewswire/ --
Bridge Biotherapeutics (KQ288330)
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 million Gross profit amounted to RMB738.5 million Adjusted non-IFRS net loss improved to RMB208.8 million, representing a significant turnaround from a negative position compared to the corresponding period of las...
Broncus Medical (02216.HK) Announces Annual Results for 2023
The treatment products R&D continue to lead, and product sales are steadily advancing. HANGZHOU, China, March 28, 2024 /PRNewswire/ -- On March 28, 2024, Broncus Medical (02216.HK) (the "Company" or "we" ) announced annual results for FY 2023. In 2023, Broncus Medical earned product sales of US...
Harbour BioMed Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncol...
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
SHANGHAI, March 28, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced it has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland GmbH to start a c...
Tigermed Reports Full Year 2023 Results
HANGZHOU, China, March 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...
Sirnaomics Announces 2023 Annual Results
Focuses on the Consolidation for Leading Projects Accelerates Clinical Trials for Core Products STP705, STP707 and STP122G HONG KONG, Germantown, Md. and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; st...
CARsgen Announced 2023 Annual Results
SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results. Business Highlights * Z...
Sanyou Bio: Sanyou's Intelligence-Enabled Innovative Biologics R&D Platform Leads in the New Era of Biological Drug Development
SHANGHAI, March 27, 2024 /PRNewswire/ -- Dr. Guojun Lang, founder and CEO of Sanyou Biopharmaceuticals provides industry insights: The new era sees the transition towards digitalization and intelligence. Following this trend, we have been thinking and planning the transformative path of digitali...
YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean
SHANGHAI, March 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a trailblazing biopharmaceutical company specializing in gene editing, is delighted to announce its participation in 2024 Cell & Gene Meeting on the Mediterranean. The event will take place fromApril 9th to 11th, 2024, at the esteemed...
Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
TAIZHOU, China, March 27, 2024 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio; stock code: 02179.HK) and Shanghai Rongsheng Biotech Co.,Ltd.(hereafter referred to as "Rongsheng Biotech") successfully held a signing and project launch meeting for new adjuvant ...
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology a...
Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology
SEONGNAM, South Korea and AURORA, Colo., March 26, 2024 /PRNewswire/ -- Bridge
Biotherapeutics (KQ288330)
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma pro...
WuXi Biologics Reports Solid 2023 Annual Results
Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew by 101.7% Y-o-Y "R" in CRDMO Thrived with Extended Part...
ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis
LYON, France, March 26, 2024 /PRNewswire/ -- Reportlinker announces the release
of the report "A White Paper To Understand The Market Structure Of Pediatric
Pertussis Hexavalent and Combination Vaccines
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients
- New research published in Clinical Cancer Research shows significant improvement in distant recurrence-free survival with combined durvalumab and tremelimumab treatment, supported by Lunit SCOPE IO's analysis of tumor microenvironment SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (K...
Week's Top Stories
Most Reposted
iKala Secures Over $20 Million in Series B+ Funding, Led by Chunghwa Telecom
[Picked up by 280 media titles]
2024-03-26 16:45Strengthening Interconnected Tourism Exchanges along the "21st Century Maritime Silk Road" Sanya Embarks on Tourism Marketing and Promotion Activities in Singapore
[Picked up by 276 media titles]
2024-03-22 21:46Chronicling ASEAN-China Friendship and Cooperation
[Picked up by 270 media titles]
2024-03-26 15:00Giti Tire Embarks on a Greener Future with New Chief Sustainability Officer
[Picked up by 263 media titles]
2024-03-25 09:00To jointly build equal, orderly multipolar world
[Picked up by 248 media titles]
2024-03-28 14:27